SRD5A2 and metastatic neoplasm: 5-alpha reductase type 2 (i.e. SRD5A2) allelic variants occur with the highest frequency in African American men and are associated with increased risk of PC and are the only individual biomarker significantly associated with 5-year risk of metastatic disease (27, 28).